ZA200409430B - Process for the manufacture of quinoline derivatives. - Google Patents
Process for the manufacture of quinoline derivatives.Info
- Publication number
- ZA200409430B ZA200409430B ZA200409430A ZA200409430A ZA200409430B ZA 200409430 B ZA200409430 B ZA 200409430B ZA 200409430 A ZA200409430 A ZA 200409430A ZA 200409430 A ZA200409430 A ZA 200409430A ZA 200409430 B ZA200409430 B ZA 200409430B
- Authority
- ZA
- South Africa
- Prior art keywords
- manufacture
- quinoline derivatives
- formula
- quinoline
- chaineded
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
- 125000002490 anilino group Chemical class [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000001924 cycloalkanes Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201778A SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Process for the manufacture of quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200409430B true ZA200409430B (en) | 2006-02-22 |
Family
ID=20288148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200409430A ZA200409430B (en) | 2002-06-12 | 2004-11-23 | Process for the manufacture of quinoline derivatives. |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1511732B9 (xx) |
| JP (1) | JP4584709B2 (xx) |
| KR (1) | KR100979216B1 (xx) |
| CN (1) | CN100418950C (xx) |
| AT (1) | ATE348814T1 (xx) |
| AU (1) | AU2003228195B2 (xx) |
| BR (1) | BR0311674A (xx) |
| CA (1) | CA2487329C (xx) |
| CY (1) | CY1107555T1 (xx) |
| DE (1) | DE60310554T2 (xx) |
| DK (1) | DK1511732T5 (xx) |
| ES (1) | ES2278160T3 (xx) |
| HR (1) | HRP20050028B1 (xx) |
| IL (1) | IL165155A (xx) |
| IS (1) | IS2975B (xx) |
| ME (1) | ME00435B (xx) |
| MX (1) | MXPA04012276A (xx) |
| NO (1) | NO329162B1 (xx) |
| NZ (1) | NZ536768A (xx) |
| PL (1) | PL210259B1 (xx) |
| PT (1) | PT1511732E (xx) |
| RS (1) | RS51021B (xx) |
| RU (1) | RU2291861C2 (xx) |
| SE (1) | SE0201778D0 (xx) |
| SI (1) | SI1511732T1 (xx) |
| UA (1) | UA78310C2 (xx) |
| WO (1) | WO2003106424A1 (xx) |
| ZA (1) | ZA200409430B (xx) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SI1937642T1 (sl) * | 2005-10-19 | 2015-01-30 | Teva Pharmaceutical Industries Ltd. | Kristali natrijevega lakvinimoda in postopek za njihovo pripravo |
| CN101466379B (zh) * | 2006-06-12 | 2012-10-31 | 泰华制药工业有限公司 | 稳定的拉喹莫德的制剂 |
| CN101578259A (zh) | 2006-11-28 | 2009-11-11 | 威朗国际制药公司 | 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物 |
| EP2234485B1 (en) | 2007-12-20 | 2013-11-13 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| KR20110048571A (ko) | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| US20120009226A1 (en) * | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| RS54707B1 (sr) | 2009-07-30 | 2016-08-31 | Teva Pharmaceutical Industries Ltd. | Tretman kronove bolesti lakvinimodom |
| PL2467372T3 (pl) | 2009-08-10 | 2017-04-28 | Teva Pharmaceutical Industries Ltd. | Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu |
| DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| US8889661B2 (en) | 2010-03-03 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of lupus nephritis using laquinimod |
| KR20130014523A (ko) | 2010-03-03 | 2013-02-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료 |
| KR20130041193A (ko) * | 2010-07-09 | 2013-04-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도 |
| AU2011275720B2 (en) * | 2010-07-09 | 2015-05-14 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| SG186948A1 (en) | 2010-07-09 | 2013-02-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| US9161935B2 (en) | 2012-02-03 | 2015-10-20 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy |
| EA201491517A1 (ru) | 2012-02-16 | 2015-03-31 | Тева Фармасьютикал Индастриз Лтд. | N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CN103626701A (zh) * | 2012-08-28 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉衍生物的方法 |
| CN103626702A (zh) * | 2012-08-30 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉酮衍生物的方法 |
| CN104955522A (zh) | 2012-11-07 | 2015-09-30 | 梯瓦制药工业有限公司 | 拉喹莫德胺盐 |
| WO2014153145A2 (en) * | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| WO2016042112A1 (en) | 2014-09-23 | 2016-03-24 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
| ES2663836T3 (es) | 2014-11-19 | 2018-04-17 | Active Biotech Ab | Carboxamidas de quinolina para su uso en el tratamiento de leucemia |
| WO2021175924A1 (en) | 2020-03-03 | 2021-09-10 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| CN111732540B (zh) * | 2020-07-20 | 2020-11-13 | 湖南速博生物技术有限公司 | 一种罗喹美克的制备方法 |
| US20230293512A1 (en) | 2020-07-23 | 2023-09-21 | Erasmus University Medical Center Rotterdam | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms |
| JP2024503372A (ja) | 2021-01-18 | 2024-01-25 | アクティブ バイオテック エイビー | 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 |
| WO2022248401A1 (en) | 2021-05-25 | 2022-12-01 | Active Biotech Ab | A plurality of tasquinimod particles and use thereof |
| IL309486A (en) | 2021-07-02 | 2024-02-01 | Active Biotech Ab | A pharmacy product containing tesquinimod and a method for evaluating the cleanliness of this product |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
-
2002
- 2002-06-12 SE SE0201778A patent/SE0201778D0/xx unknown
-
2003
- 2003-05-14 AT AT03725956T patent/ATE348814T1/de active
- 2003-05-14 JP JP2004513257A patent/JP4584709B2/ja not_active Expired - Lifetime
- 2003-05-14 ES ES03725956T patent/ES2278160T3/es not_active Expired - Lifetime
- 2003-05-14 NZ NZ536768A patent/NZ536768A/en not_active IP Right Cessation
- 2003-05-14 CA CA2487329A patent/CA2487329C/en not_active Expired - Lifetime
- 2003-05-14 UA UA20041109639A patent/UA78310C2/xx unknown
- 2003-05-14 ME MEP-2008-656A patent/ME00435B/me unknown
- 2003-05-14 RU RU2005100054/04A patent/RU2291861C2/ru not_active IP Right Cessation
- 2003-05-14 SI SI200330688T patent/SI1511732T1/sl unknown
- 2003-05-14 DK DK03725956T patent/DK1511732T5/da active
- 2003-05-14 MX MXPA04012276A patent/MXPA04012276A/es active IP Right Grant
- 2003-05-14 BR BRPI0311674-3A patent/BR0311674A/pt not_active Application Discontinuation
- 2003-05-14 RS YUP-1076/04A patent/RS51021B/sr unknown
- 2003-05-14 PL PL373817A patent/PL210259B1/pl unknown
- 2003-05-14 CN CNB038135310A patent/CN100418950C/zh not_active Expired - Lifetime
- 2003-05-14 EP EP03725956A patent/EP1511732B9/en not_active Expired - Lifetime
- 2003-05-14 AU AU2003228195A patent/AU2003228195B2/en not_active Expired
- 2003-05-14 PT PT03725956T patent/PT1511732E/pt unknown
- 2003-05-14 KR KR1020047020088A patent/KR100979216B1/ko not_active Expired - Lifetime
- 2003-05-14 HR HRP20050028AA patent/HRP20050028B1/hr not_active IP Right Cessation
- 2003-05-14 WO PCT/SE2003/000780 patent/WO2003106424A1/en not_active Ceased
- 2003-05-14 DE DE60310554T patent/DE60310554T2/de not_active Expired - Lifetime
-
2004
- 2004-11-11 IL IL165155A patent/IL165155A/en active IP Right Grant
- 2004-11-23 ZA ZA200409430A patent/ZA200409430B/xx unknown
- 2004-11-24 IS IS7550A patent/IS2975B/is unknown
- 2004-12-29 NO NO20045703A patent/NO329162B1/no not_active IP Right Cessation
-
2007
- 2007-03-01 CY CY20071100295T patent/CY1107555T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL165155A0 (en) | Process for the manufacture of quinoline derivatives | |
| NO20044767L (no) | Farmasoytisk formulering med modifisert frigjoring | |
| BRPI0408160B1 (pt) | Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo | |
| MY141020A (en) | Novel pparalpha and ppargamma agonists | |
| NO20055099L (no) | Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner | |
| WO2003080631A8 (en) | Plasma carboxypeptidase b inhibitors | |
| WO2003024913A1 (en) | SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY | |
| MY145980A (en) | Process for the preparation of poly(silyl esters)s, and their uses | |
| NO20031046D0 (no) | Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse | |
| TW200720234A (en) | Hydroxynaphthalenedicarboxylic acid hydrazide and derivatives thereof as well as process for preparing them | |
| AU5209600A (en) | Orally active androgens | |
| WO2003014094A3 (de) | Heterocyclylarylsulfonamide | |
| NO20055924L (no) | Metode for fremstilling av (2s)-3-(4- {2-[Amino]-2-Oksoetoksy}Fenyl)-2-Etoksypropansyrederivater | |
| WO2001083423A3 (en) | 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof | |
| JPS55154950A (en) | Novel carboxylic acid amide derivative | |
| ES2184633A1 (es) | Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida. | |
| ATE337348T1 (de) | Beschichtungen aus speziellen polyolen und oxalsäure | |
| TW200621807A (en) | Cellulose derivative composition, cellulose derivative film and trialkoxybenzoic acid deriv ative compound | |
| NO20044045L (no) | Ny fremgangsmate | |
| UA42554A (uk) | Спосіб отримання 7-заміщених 3-метил-8-(піперазиніл-1) ксантинів, що мають антианафілактичну активність |